Jentadueto™ tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
List view / Grid view
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
24 May 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African…
25 August 2011 | By Eli Lilly and Company, Boehringer Ingelheim
Linagliptin is the only DPP-4 inhibitor to be approved at one dosage strength for adults with type 2 diabetes in Europe, without any need for dose adjustments...
AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across…